Consistent with this finding, Landi et al. found no significant differences in newly diagnosed urinary incontinence in patients under endocrine therapy with tamoxifen or aromatase inhibitors and breast cancer patients without endocrine therapy adjusted for age, time since diagnosis, race, parity, smoking status, hysterectomy history, and BMI [50]. Here, CYP19A1 is linked to breast cancer.